<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857909</url>
  </required_header>
  <id_info>
    <org_study_id>MED.RES:HOS:SKM.02.2009</org_study_id>
    <nct_id>NCT00857909</nct_id>
  </id_info>
  <brief_title>The Effect of Amiloride and Spironolactone in Healthy Persons</brief_title>
  <acronym>SPAS</acronym>
  <official_title>The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether retaining potassium in the body will lead to changes in
      blood pressure and changes in blood and urine samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose is to measure the effect of amiloride and spironolactone on:

        1. Renal function (GFR, u-AQP2, u-ENaCÎ², u-cAMP, u-PGE2, CH20, FENa, FEK),

        2. Pulsbewave velocity, augmentation index and central blood pressure,

        3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and

        4. Ambulatory blood pressure
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Randomisation 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomisation 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spironolactone 25 mg twice daily, to be compared with placebo and amiloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>calcium tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>1 tablet twice a day</description>
    <arm_group_label>Randomisation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>1 tablet twice a day</description>
    <arm_group_label>Randomisation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and spironolactone</intervention_name>
    <description>5mg twice daily</description>
    <arm_group_label>Randomisation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25mg twice daily</description>
    <arm_group_label>Randomisation 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Non-smokers

        Exclusion Criteria:

          -  Smoking

          -  Under medical treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erling B Pedersen, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Erling Bjerregaard Pedersen/ Dr. Med</name_title>
    <organization>Medical Research Department</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

